CompletedNCT02777931
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
Researchers compared NFC-1 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Medication studyAges 12–17United States
Understand this study
What did researchers investigate?
Researchers compared NFC-1 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who was this study for?
Listed age limits: 12 years to 17 years.
- Listed locations
- Baltimore, United StatesSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJune 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 101
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT02777931
- Official title
Show the full official title
A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD
Recruitment & locations
CompletedBaltimore
Questions about this study
What did researchers investigate?
Researchers compared NFC-1 and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who is behind this study?
The study sponsor is Aevi Genomic Medicine, LLC, a Cerecor company, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including NFC-1 and Placebo.
Who was this study for?
Listed age limits: 12 years to 17 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
Researchers compared MG01CI (1400 mg) and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
CompletedNCT00500149
Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD
United States
CompletedNCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
United States